Skip to main content
Clinical Trials/NCT01964677
NCT01964677CompletedNot Applicable

Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - a Multicenter Study

Institute of Cancer Research, United Kingdom2 sites in 1 country12 target enrollmentStarted: January 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
12
Locations
2
Primary Endpoint
Pain response

Study Overview

Brief Summary

The aim of this study is to evaluate effectiveness of the Philips Sonalleve MR-HIFU device for the palliation of pain in patients with bone metastases.

Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) uses ultrasound to palliate pain caused by bone metastases. The main palliative mechanism of the method is due to local bone denervation, caused by the heat denaturation of the periosteum layer in the treated area. The importance of this therapy is that it offers a non-invasive, focal therapy, avoiding side-effects to surrounding normal tissue that occur with radiation therapy or the need for needle insertion as with radio-frequency(RF)ablation.

The study hypothesis is that MR-HIFU will be effective in treating the pain associated with bone metastases

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • radiologic evidence of bone metastases from any solid tumour
  • diagnosis of dominant painful bone metastasis
  • target lesion less than 8cm

Exclusion Criteria

  • primary bone tumours rather than metastases
  • Inability to tolerate stationary position during treatment
  • pregnancy
  • MRI incompatible metal implants

Arms & Interventions

MR-HIFU of painful bone metastases

Experimental

Intervention: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU) (Device)

Outcomes

Primary Outcomes

Pain response

Time Frame: 30 days post-treatment

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Institute of Cancer Research, United Kingdom
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

NdeSouza

Professor of Translational Imaging

Institute of Cancer Research, United Kingdom

Study Sites (2)

Loading locations...

Similar Trials